⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMMX News
Immix Biopharma, Inc. Common Stock
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
globenewswire.com
IMMX
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
globenewswire.com
IMMX
Form 8-K
sec.gov
IMMX
Immix Biopharma to Participate in Upcoming Investor Conferences
globenewswire.com
IMMX
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
globenewswire.com
IMMX
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
IMMX
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
IMMX